Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 10/04/2023
Date Insider Type Main position Quantity % Market Cap.
10/4/23 Free

Executive/Senior Manager

400,000 0.6684%
1/2/23 Free

Chief Technology Officer

400,000 0.6686%
1/2/23 Free

Chief Operating Officer

400,000 0.6686%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 2.95M
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -3.16%-1.93%+59.31%+192.41% 31.33B
Weighted average by Cap. -1.93%-1.50%+57.15%+152.82%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock